Asset profile
BP1001
Unknown / undisclosed
Evidence outlook · lead readout
NCT01159028 · Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Ph1 Positive CML
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT01159028: This was an open-label, single-arm dose-escalation study with no control group, designed to establish a tolerable dose rather than to test efficacy; results have not yet been reported.
The published analysis covers the 39 patients actually treated, fewer than the study's planned enrollment of 60.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
December 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.